Amber Doiron, assistant professor of bioengineering, says current methods of assessing atherosclerosis — commonly known as hardening of the arteries — are not terribly accurate. Some 30 percent of deaths worldwide can be attributed to the disease, which occurs when fat, cholesterol and other particles form hard structures called plaques in the walls of arteries.

“It’s really a guessing game right now,” she says. “Doctors use factors like blood pressure and cholesterol level to get an idea of a patient’s risk. Then they use plaque size as a general measure of whether a person has the disease. But there’s a fairly poor correlation between plaque size and heart attack or stroke.”

Doiron, who has an interest in molecular imaging as well as expertise in nanoscience, wants to help physicians do a better job of identifying which plaques are cause for concern.

She and a Temple University colleague recently received a two-year, $418,000 grant from the National Institute of Biomedical Imaging and Bioengineering to support this project. It’s a notable success in part because this was Doiron’s first National Institutes of Health grant proposal.

The researchers will use a combination of polymers and superparamagnetic iron oxide nanoparticles for the study. The nanoparticle is sensitive to oxidative stress, which occurs in atherosclerosis and has been linked to patients who have a higher prevalence of heart attack and stroke. Using an MRI scan, the researchers will be able to see how active the nanoparticle is, which will indicate whether the plaque is stable.

“A stroke or a heart attack doesn’t necessarily come when a plaque fully blocks the flow of blood through an artery,” Doiron explains. “What happens is the plaque ruptures and the gunk that underlies the plaque is exposed to blood and a clot forms. The clot builds quickly — on an hour time scale as opposed to over years — and the clot can grow there until it blocks flow, or it can dislodge and block flow somewhere else. Most heart attacks do not occur from a full blockage of plaque. It happens because the plaque bursts. Same thing with strokes. That’s why size isn’t necessarily indicative of how dangerous a plaque is.”

The discovery of a molecule or a cell type that indicated which plaques are safe and which ones are dangerous would be a huge breakthrough, Doiron says. She thinks oxidative stress may be such an indicator.

“Atherosclerosis is an incredibly complex disease that progresses over decades,” Doiron says. “It’s hard to tell who’s walking around with plaques that are stable, relatively safe, and who has plaques that may cause a heart attack tomorrow. For some patients, the first sign of trouble is a heart attack.”

Medications like the insulin she has injected every day since she was 16.

Now, as a biochemistry and neuroscience major at Binghamton University, she’s taking the first steps: helping to understand how nanoparticles can improve rechargeable batteries.

There’s no disconnect here: The skills and knowledge she’ll acquire working on Assistant Professor Gretchen Mahler’s project can be taken in many directions.

The connection, MacAneney said, is this: Industry leaders are interested in using nanoparticles of vanadium oxide as a cathode in rechargeable lithium ion batteries. “But before they can use nanoparticles in batteries, they need to understand the health effects,” she said, both on production workers making the products and the everyday user.

Vanadium in various forms can help lithium batteries store more energy, discharge more power and recharge faster — perfect for any number of smart energy projects from hybrid-electric or all-electric vehicles to household energy storage.

That is, if it doesn’t harm people. Acute vanadium oxide exposure in its larger form has been linked to increased bronchial infections, pneumonia, inflamed tissues and irritated eyes, throat, lungs and nasal tissue — even nervous disorders and paralysis. The health effects of vanadium oxide nanoparticles have never been studied.

“Our hypothesis is that when these nanoparticles come in contact with epithelial cells, it’ll cause inflammation and absorption,” MacAneney said.

The data will help Mahler and a colleague at the State University of New York at Potsdam to prepare a proposal for grant funding. And it’s a good project to help put a new researcher through her paces, using newly acquired skills from eight weeks of lab training.

“I put them through a pretty rigorous training program,” Mahler said. It weeds out people unsuited to a life of research and keeps the new researcher and her colleagues safe. “She is just starting to dive into the nanoparticle work.”

But understanding how a body can absorb nanoparticles relates directly to McAneney’s interest in medication. Insulin today cannot easily survive gastric acids, making oral insulin impractical.

“But can you encapsulate it in something to protect it?” she asked. “It wouldn’t degrade in the stomach.”

Interesting question, and one McAneney plans to keep asking on her way to a doctorate and perhaps a medical degree, too.